A Novel 8-Gene Prognostic Signature for Survival Prediction of Uveal Melanoma

Figure 6

Decision curve analysis for each model in the validation cohort. The -axis measures the net benefit. The net benefit was calculated by summing the benefits (true-positive results) and subtracting the harms (false-positive results), weighting the latter by a factor related to the relative harm of an undetected metastasis compared with the harm of unnecessary treatment. The UMPS or the combined UMPS and AJCC TNM staging model had the higher net benefit compared with the AJCC TNM staging system in 10% threshold probabilities.